Table 2.
PHD1, PHD2 and PHD3 expression before and after treatment in matched cases
| Before n (%) | After n (%) | P value | ||
|---|---|---|---|---|
| PHD1 | Overall (n = 130) | |||
| 0 | 87 (66.9) | 19 (14.6) | 0.0000 | |
| 1 | 39 (30.0) | 68 (53.3) | ||
| 2 | 3 (2.3) | 36 (27.7) | ||
| 3 | 1 (0.8) | 7 (5.4) | ||
| EPI (n = 64) | ||||
| 0 | 40 (62.5) | 8 (12.5) | 0.0000 | |
| 1 | 23 (35.9) | 32 (50.0) | ||
| 2 | 1 (1.6) | 23 (35.9) | ||
| 3 | 1 (1.6) | |||
| EPI-TAM (n = 66) | ||||
| 0 | 47 (71.2) | 11 (16.7) | 0.0000 | |
| 1 | 16 (24.2) | 36 (54.5) | ||
| 2 | 2 (3.0) | 13 (19.7) | ||
| 3 | 1 (1.5) | 6 (9.1) | ||
| PHD2 | Overall (n = 111) | |||
| 0 | 62 (55.9%) | 13 (11.7%) | 0.0000 | |
| 1 | 31 (27.9%) | 15 (13.6%) | ||
| 2 | 16 (14.4%) | 43 (38.7%) | ||
| 3 | 2 (1.8%) | 40 (36.0%) | ||
| EPI (n = 59) | ||||
| 0 | 31 (52.5) | 5 (8.5) | 0.0000 | |
| 1 | 16 (27.1) | 6 (10.2) | ||
| 2 | 10 (16.9) | 22 (37.3) | ||
| 3 | 2 (3.4) | 26 (44.1) | ||
| EPI-TAM (n = 52) | ||||
| 0 | 31 (59.6) | 8 (15.4) | 0.0000 | |
| 1 | 15 (28.8) | 9 (17.3) | ||
| 2 | 6 (11.5) | 21(40.4) | ||
| 3 | 0 | 14 (26.9) | ||
| PHD3 | Overall (n = 127) | |||
| 0 | 69/127 (54.3%) | 8/127 (6.3%) | 0.00 | |
| 1 | 46/127 (36.2%) | 47/127 (37.0%) | ||
| 2 | 12/127 (9.4%) | 47/127 (37.0%) | ||
| 3 | 0.00 | 25/127 (19.7%) | ||
| EPI (n = 63) | ||||
| 0 | 29/63(46.0%) | 3/63(4.8%) | 0.00 | |
| 1 | 27/63 (42.8%) | 22/63 (34.9%) | ||
| 2 | 7/63 (11.1%) | 23/63 (36.5%) | ||
| 3 | 0.00 | 15/63 (23.8%) | ||
| EPI-TAM (n = 64) | ||||
| 0 | 40/64 (62.5%) | 5/64 (7.8%) | 0.00 | |
| 1 | 19/64 (29.7%) | 25/64 (39.1%) | ||
| 2 | 5/64 (7.8%) | 24/64 (37.5%) | ||
| 3 | 0.00 | 10/64 (15.6%) |
EPI, epirubicin treatment; EPI-TAM, epirubicin plus tamoxifen treatment; PHD, prolyl hydroxylase.